2 1 Shi Ji Jing Ji Bao Dao·2025-11-14 03:29Core Insights - The global diabetes patient population is projected to reach 589 million by 2024, with China having the highest number of patients aged 20-79 at 148 million, expected to rise to 168 million by 2050 [1][2] - Continuous Glucose Monitoring (CGM) technology is rapidly replacing traditional methods due to its accuracy and convenience, becoming a key growth area in diabetes management [1][3] Industry Overview - The domestic CGM market is divided into two main camps: imported brands like Abbott and domestic companies such as Sanofi and Yuyue Medical, which are competing by lowering costs and enhancing product differentiation [2][4] - The CGM market is expected to grow significantly, with a projected market size of 71.8 billion yuan by 2025 and a compound annual growth rate of 14.49% until 2032, reaching 185.2 billion yuan [3][4] Company Performance - Sanofi reported a revenue of 3.453 billion yuan in the first three quarters, an increase of 8.52%, with a net cash flow from operating activities of 537 million yuan, up 33.25% [4] - Yuyue Medical has invested 2.375 billion yuan in R&D from 2020 to 2024, with CGM products becoming a significant growth driver, achieving a revenue of 6.545 billion yuan in the first three quarters of 2025 [4][5] Technological Advancements - The integration of AI in CGM products is enhancing their capabilities, with Yuyue Medical's new Anytime series achieving global leading technical standards [5][6] - The CGM technology is evolving from simple monitoring to a comprehensive diabetes management system, enabling personalized interventions based on data analysis [6][9] Market Dynamics - Domestic CGM companies are rapidly gaining market share by offering products at 30%-50% lower prices than international competitors, aided by favorable healthcare policies [2][4] - The shift from low-cost market filling to comprehensive capability building is evident, with domestic firms focusing on both mid-range and high-end market segments [6][9] Challenges and Opportunities - Domestic CGM companies face challenges such as regulatory compliance and operational costs, particularly in decentralized healthcare settings [7][8] - There is a need for improved training and data integration in grassroots healthcare to enhance the effectiveness of CGM products [8][9] Future Outlook - The CGM market is poised for significant growth, driven by technological advancements and increasing demand for chronic disease management solutions [3][9] - The potential for Chinese CGM companies to transition from domestic players to global competitors hinges on overcoming regulatory hurdles and enhancing product capabilities [7][9]